Cover Image
市場調查報告書

妥瑞氏症候群 : 開發平台分析

Tourette Syndrome - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 251634
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
妥瑞氏症候群 : 開發平台分析 Tourette Syndrome - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 71 Pages
簡介

妥瑞氏症候群(TS)是神經病變的一種,特徵是會重覆不自主的行動、發音(稱之為tics)。主要的前兆有眨眼等眼睛迅速運動、顏面扭曲、聳肩、搖頭、肩頸抽搐等。其他還有用鼻子接觸物品去嗅氣味,拍打自己的手腳等症狀。致病危險因子為年齡等,此外男性發病的可能性為女性的3∼4倍。主要的治療方法有抗憂鬱劑和興奮藥,行動療法等。

本報告提供全球各國治療妥瑞氏症候群所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

妥瑞氏症候群概要

治療藥的開發

  • 妥瑞氏症候群開發中產品:概要
  • 妥瑞氏症候群開發中產品:比較分析

各企業開發中的妥瑞氏症候群治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 不明確的階段的產品

妥瑞氏症候群治療藥:開發中的產品一覽(各企業)

妥瑞氏症候群開發治療藥的企業

  • AstraZeneca PLC
  • Catalyst Pharmaceutical Partners, Inc.
  • Edison Pharmaceuticals, Inc.
  • Neurocrine Biosciences, Inc.
  • Psyadon Pharmaceuticals, Inc.
  • Reviva Pharmaceuticals Inc.
  • Synchroneuron Inc.
  • Teva Pharmaceutical Industries Limited

妥瑞氏症候群:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • acamprosate calcium SR
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • AZD-5213
  • CPP-115
  • dutetrabenazine ER
  • ecopipam hydrochloride
  • RP-5063
  • valbenazine
  • vatiquinone
  • vigabatrin

妥瑞氏症候群治療藥:開發中產品的最新趨勢

妥瑞氏症候群治療藥:開發暫停的產品

妥瑞氏症候群治療藥:開發中止的產品

妥瑞氏症候群相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8955IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Pipeline Review, H1 2017, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Unknown stages are 7, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tourette Syndrome - Overview
  • Tourette Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tourette Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tourette Syndrome - Companies Involved in Therapeutics Development
  • Catalyst Pharmaceuticals Inc
  • Neurocrine Biosciences Inc
  • Psyadon Pharmaceuticals Inc
  • Reviva Pharmaceuticals Inc
  • Synchroneuron Inc
  • Teva Pharmaceutical Industries Ltd
  • Therapix Biosciences Ltd
  • Tourette Syndrome - Drug Profiles
  • (amfetamine + guanfacine hydrochloride) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • acamprosate calcium SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CPP-115 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • deutetrabenazine ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dronabinol + palmidrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ecopipam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RP-5063 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • valbenazine tosylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vigabatrin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tourette Syndrome - Dormant Projects
  • Tourette Syndrome - Discontinued Products
  • Tourette Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Jan 17, 2017: Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette's Syndrome in Children
  • Jan 17, 2017: Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA (valbenazine) in Adults with Tourette Syndrome
  • Jan 04, 2017: Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Yale University for Treating Tourette's Syndrome Using Cannabinoid-based Drug
  • Aug 31, 2016: Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA for VMAT2 Inhibitor Valbenazine
  • Jul 28, 2016: Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
  • Jun 15, 2016: Therapix Biosciences Filed an Application with the FDA to Approve an Orphan Designation for the Drug Developed Based on the Entourage Technology for Treating Tourettes Syndrome
  • Feb 03, 2016: Psyadon Announces Positive Independent Review of Phase 2b Study of Ecopipam for the Treatment of Tourette's Syndrome in Children
  • Feb 02, 2016: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
  • Dec 16, 2015: Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
  • Oct 20, 2015: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
  • Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population
  • Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
  • May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome in Children Ages 7-17
  • Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome
  • Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Tourette Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc, H1 2017
  • Tourette Syndrome - Pipeline by Neurocrine Biosciences Inc, H1 2017
  • Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals Inc, H1 2017
  • Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
  • Tourette Syndrome - Pipeline by Synchroneuron Inc, H1 2017
  • Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Tourette Syndrome - Pipeline by Therapix Biosciences Ltd, H1 2017
  • Tourette Syndrome - Dormant Projects, H1 2017
  • Tourette Syndrome - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Tourette Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top